Table 2. The risk of diagnosed rosacea according to chronic systemic diseases, which is related to cardiovascular risk factors, and drugs.

Variable	Rosacea	Without rosacea	Total population (n)	p-value	95% confidence interval	Odds ratio
Diabetes	7 (0.5)	1,418 (99.5)	1,425	0.016*	1.295~5.730	2.724
Hypertension	101 (0.2)	46,503 (99.8)	46,604	0.073	0.987~1.470	1.205
Cerebral infarction	12 (0.1)	15,241 (99.9)	15,253	0.003**	0.244~0.760	0.431
PAOD	0 0	33 (100)	33	1.000
Dyslipidemia	88 (0.3)	27,534 (99.7)	27,622	0.000***	1.445~2.212	1.788
IHD	4 (0.2)	2,540 (99.8)	2,544	1.000	0.325~2.314	0.867
α-Blocker	16 (0.4)	4,504 (99.6)	4,520	0.006**	1.200~3.212	1.963
BB	239 (0.5)	52,582 (99.5)	52821	0.000***	3.512~4.419	3.939
CCB	65 (0.2)	33,792 (99.8)	33,857	0.611	0.975~1.629	1.061
Diuretics	60 (0.2)	31,052 (99.8)	31,112	0.596	0.825~1.377	1.066
ACEi	15 (0.2)	7,431 (99.8)	7,446	0.680	0.669~1.849	0.899
ARB	55 (0.2)	23,350 (99.8)	23,405	0.058	0.998~1.704	0.767
HMG-CoA reductase inhibitor	186 (0.2)	75,534 (99.8)	75,720	0.000***	1.390~1.839	1.599
Fibates	19 (0.3)	6,323 (99.7)	6,342	0.026*	1.056~2.609	1.660
Cholestyramine	0 0	153 (100)	153	1.000
ASA	69 (0.2)	43026 (99.8)	43095	0.509	0.726~1.172	0.923

Values are presented as number (%). PAOD: peripheral arterial occlusive disease, IHD: ischemic heart disease, BB: β-blocker, CCB: calcium channel blocker, ACEi: angiotensin-converting-enzyme inhibitor, ARB: angiotensin II receptor blocker, HMG-CoA: [beta]-hydroxy-[beta]-methylglutaryl coenzyme A, ASA: aspirin. ^*p<0.05, ^**p<0.01, ^***p<0.001.